Hospitalizations in patients with idiopathic pulmonary fibrosis

IPF-PRO Registry investigators; Hyun J. Kim; Laurie D. Snyder; Ayodeji Adegunsoye; Megan L. Neely; Shaun Bender; Eric S. White; Craig S. Conoscenti; Mary E. Strek

doi:10.1186/s12931-021-01851-4

Hospitalizations in patients with idiopathic pulmonary fibrosis

IPF-PRO Registry investigators, Hyun J. Kim, Laurie D. Snyder, Ayodeji Adegunsoye, Megan L. Neely, Shaun Bender, Eric S. White, Craig S. Conoscenti, Mary E. Strek

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

19 Downloads (Pure)

Abstract

Background: Hospitalizations are common among patients with idiopathic pulmonary fibrosis (IPF). We investigated the impact of hospitalizations on outcomes in patients with IPF. Methods: The IPF-PRO Registry is an observational US registry that enrolled patients with IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months. Associations between patient characteristics and hospitalization, and between hospitalization and mortality, were analyzed using Cox regression models. Results: A total of 1002 patients with IPF were enrolled into the IPF-PRO Registry. Over a median follow-up time of 23.7 months (maximum: 67.0 months), 568 patients (56.7%) had at least one hospitalization. Of these patients, 319 (56.2%) had at least one respiratory-related hospitalization and 120 (21.1%) had at least one hospitalization with ventilatory support. Younger age (HR 0.68 [95% CI 0.55, 0.84] per 5-year increase for patients < 62 years), lower BMI (0.96 [0.93, 0.98] per 1-point increase), lower FVC % predicted (0.90 [0.83, 0.97] per 10% increase), oxygen use at rest (2.85 [2.18, 3.72]) and history of pulmonary hypertension (2.02 [1.37, 2.96]) at enrollment were associated with an increased risk of respiratory-related hospitalization during follow-up. In a multivariable model, there was an eightfold increase in the risk of mortality during hospitalization or within 90 days of discharge compared with outside of this period. The risk of mortality associated with a respiratory hospitalization or a hospitalization with ventilatory support was even greater. Conclusions: Data from the IPF-PRO Registry demonstrate that hospitalizations are common among patients with IPF. The risk of mortality during hospitalization or within 90 days of discharge was high, particularly among patients who were hospitalized for a respiratory cause or received ventilatory support. Trial registration ClinicalTrials.gov, NCT01915511. Registered 5 August 2013, https://clinicaltrials.gov/ct2/show/NCT01915511.

Original language	English (US)
Article number	257
Journal	Respiratory research
Volume	22
Issue number	1
DOIs	https://doi.org/10.1186/s12931-021-01851-4
State	Published - Dec 2021

Bibliographical note

Funding Information:
HJK is a member of the Publication Committee for the IPF-PRO/ILD-PRO Registry. LDS and MLN are faculty members in the Duke Clinical Research Institute (DCRI), which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc to co-ordinate the IPF-PRO/ILD-PRO Registry. AA reports grants and personal fees from Boehringer Ingelheim, personal fees from Genentech and grants from the Pulmonary Fibrosis Foundation and the National Institutes of Health. SB, ESW and CSC are employees of Boehringer Ingelheim Pharmaceuticals, Inc. MES reports grants, personal fees and non-financial support from Boehringer Ingelheim; grants from Galapagos; and personal fees from FibroGen.

Funding Information:
The IPF-PRO™ Registry is funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and co-ordinated by the Duke Clinical Research Institute (DCRI).

Funding Information:
The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for development of this article. Writing support was provided by Julie Fleming and Wendy Morris of Fleishman-Hillard, London, UK, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. Boehringer Ingelheim was given the opportunity to review the article for medical and scientific accuracy as well as intellectual property considerations.

Publisher Copyright:
© 2021, The Author(s).

Keywords

Interstitial lung disease
Mechanical ventilation
Mortality
Pulmonary fibrosis
Respiratory function tests

PubMed: MeSH publication types

Journal Article
Multicenter Study
Observational Study

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1186/s12931-021-01851-4License: CC BY

s12931-021-01851-4Final published version, 0.99 MBLicense: CC BY

https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-021-01851-4

Find It

Find It at U of M Libraries

Cite this

@article{e2dc25c0eb314eb8a1ea9166c931f722,

title = "Hospitalizations in patients with idiopathic pulmonary fibrosis",

abstract = "Background: Hospitalizations are common among patients with idiopathic pulmonary fibrosis (IPF). We investigated the impact of hospitalizations on outcomes in patients with IPF. Methods: The IPF-PRO Registry is an observational US registry that enrolled patients with IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months. Associations between patient characteristics and hospitalization, and between hospitalization and mortality, were analyzed using Cox regression models. Results: A total of 1002 patients with IPF were enrolled into the IPF-PRO Registry. Over a median follow-up time of 23.7 months (maximum: 67.0 months), 568 patients (56.7%) had at least one hospitalization. Of these patients, 319 (56.2%) had at least one respiratory-related hospitalization and 120 (21.1%) had at least one hospitalization with ventilatory support. Younger age (HR 0.68 [95% CI 0.55, 0.84] per 5-year increase for patients < 62 years), lower BMI (0.96 [0.93, 0.98] per 1-point increase), lower FVC % predicted (0.90 [0.83, 0.97] per 10% increase), oxygen use at rest (2.85 [2.18, 3.72]) and history of pulmonary hypertension (2.02 [1.37, 2.96]) at enrollment were associated with an increased risk of respiratory-related hospitalization during follow-up. In a multivariable model, there was an eightfold increase in the risk of mortality during hospitalization or within 90 days of discharge compared with outside of this period. The risk of mortality associated with a respiratory hospitalization or a hospitalization with ventilatory support was even greater. Conclusions: Data from the IPF-PRO Registry demonstrate that hospitalizations are common among patients with IPF. The risk of mortality during hospitalization or within 90 days of discharge was high, particularly among patients who were hospitalized for a respiratory cause or received ventilatory support. Trial registration ClinicalTrials.gov, NCT01915511. Registered 5 August 2013, https://clinicaltrials.gov/ct2/show/NCT01915511.",

keywords = "Interstitial lung disease, Mechanical ventilation, Mortality, Pulmonary fibrosis, Respiratory function tests",

author = "{IPF-PRO Registry investigators} and Kim, {Hyun J.} and Snyder, {Laurie D.} and Ayodeji Adegunsoye and Neely, {Megan L.} and Shaun Bender and White, {Eric S.} and Conoscenti, {Craig S.} and Strek, {Mary E.} and Scott Beegle and Belperio, {John A.} and Rany Condos and Francis Cordova and Culver, {Daniel A.} and Daniel Dilling and John Fitzgerald and Leann Silhan and Flaherty, {Kevin R.} and Kevin Gibson and Mridu Gulati and Kalpalatha Guntupalli and Nishant Gupta and {Hajari Case}, Amy and David Hotchkin and Huie, {Tristan J.} and Kaner, {Robert J.} and Kim, {Hyun J.} and Lancaster, {Lisa H.} and Mark Steele and Lasky, {Joseph A.} and Doug Lee and Timothy Liesching and Randolph Lipchik and Jason Lobo and Luckhardt, {Tracy R.} and Andrade, {Joao A.} and Yolanda Mageto and Yolanda Mageto and David Zhang",

note = "Funding Information: HJK is a member of the Publication Committee for the IPF-PRO/ILD-PRO Registry. LDS and MLN are faculty members in the Duke Clinical Research Institute (DCRI), which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc to co-ordinate the IPF-PRO/ILD-PRO Registry. AA reports grants and personal fees from Boehringer Ingelheim, personal fees from Genentech and grants from the Pulmonary Fibrosis Foundation and the National Institutes of Health. SB, ESW and CSC are employees of Boehringer Ingelheim Pharmaceuticals, Inc. MES reports grants, personal fees and non-financial support from Boehringer Ingelheim; grants from Galapagos; and personal fees from FibroGen. Funding Information: The IPF-PRO{\texttrademark} Registry is funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and co-ordinated by the Duke Clinical Research Institute (DCRI). Funding Information: The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for development of this article. Writing support was provided by Julie Fleming and Wendy Morris of Fleishman-Hillard, London, UK, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. Boehringer Ingelheim was given the opportunity to review the article for medical and scientific accuracy as well as intellectual property considerations. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s12931-021-01851-4",

language = "English (US)",

volume = "22",

journal = "Respiratory research",

issn = "1465-9921",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Hospitalizations in patients with idiopathic pulmonary fibrosis

AU - IPF-PRO Registry investigators

AU - Kim, Hyun J.

AU - Snyder, Laurie D.

AU - Adegunsoye, Ayodeji

AU - Neely, Megan L.

AU - Bender, Shaun

AU - White, Eric S.

AU - Conoscenti, Craig S.

AU - Strek, Mary E.

AU - Beegle, Scott

AU - Belperio, John A.

AU - Condos, Rany

AU - Cordova, Francis

AU - Culver, Daniel A.

AU - Dilling, Daniel

AU - Fitzgerald, John

AU - Silhan, Leann

AU - Flaherty, Kevin R.

AU - Gibson, Kevin

AU - Gulati, Mridu

AU - Guntupalli, Kalpalatha

AU - Gupta, Nishant

AU - Hajari Case, Amy

AU - Hotchkin, David

AU - Huie, Tristan J.

AU - Kaner, Robert J.

AU - Kim, Hyun J.

AU - Lancaster, Lisa H.

AU - Steele, Mark

AU - Lasky, Joseph A.

AU - Lee, Doug

AU - Liesching, Timothy

AU - Lipchik, Randolph

AU - Lobo, Jason

AU - Luckhardt, Tracy R.

AU - Andrade, Joao A.

AU - Mageto, Yolanda

AU - Zhang, David

N1 - Funding Information: HJK is a member of the Publication Committee for the IPF-PRO/ILD-PRO Registry. LDS and MLN are faculty members in the Duke Clinical Research Institute (DCRI), which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc to co-ordinate the IPF-PRO/ILD-PRO Registry. AA reports grants and personal fees from Boehringer Ingelheim, personal fees from Genentech and grants from the Pulmonary Fibrosis Foundation and the National Institutes of Health. SB, ESW and CSC are employees of Boehringer Ingelheim Pharmaceuticals, Inc. MES reports grants, personal fees and non-financial support from Boehringer Ingelheim; grants from Galapagos; and personal fees from FibroGen. Funding Information: The IPF-PRO™ Registry is funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and co-ordinated by the Duke Clinical Research Institute (DCRI). Funding Information: The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for development of this article. Writing support was provided by Julie Fleming and Wendy Morris of Fleishman-Hillard, London, UK, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. Boehringer Ingelheim was given the opportunity to review the article for medical and scientific accuracy as well as intellectual property considerations. Publisher Copyright: © 2021, The Author(s).

PY - 2021/12

Y1 - 2021/12

N2 - Background: Hospitalizations are common among patients with idiopathic pulmonary fibrosis (IPF). We investigated the impact of hospitalizations on outcomes in patients with IPF. Methods: The IPF-PRO Registry is an observational US registry that enrolled patients with IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months. Associations between patient characteristics and hospitalization, and between hospitalization and mortality, were analyzed using Cox regression models. Results: A total of 1002 patients with IPF were enrolled into the IPF-PRO Registry. Over a median follow-up time of 23.7 months (maximum: 67.0 months), 568 patients (56.7%) had at least one hospitalization. Of these patients, 319 (56.2%) had at least one respiratory-related hospitalization and 120 (21.1%) had at least one hospitalization with ventilatory support. Younger age (HR 0.68 [95% CI 0.55, 0.84] per 5-year increase for patients < 62 years), lower BMI (0.96 [0.93, 0.98] per 1-point increase), lower FVC % predicted (0.90 [0.83, 0.97] per 10% increase), oxygen use at rest (2.85 [2.18, 3.72]) and history of pulmonary hypertension (2.02 [1.37, 2.96]) at enrollment were associated with an increased risk of respiratory-related hospitalization during follow-up. In a multivariable model, there was an eightfold increase in the risk of mortality during hospitalization or within 90 days of discharge compared with outside of this period. The risk of mortality associated with a respiratory hospitalization or a hospitalization with ventilatory support was even greater. Conclusions: Data from the IPF-PRO Registry demonstrate that hospitalizations are common among patients with IPF. The risk of mortality during hospitalization or within 90 days of discharge was high, particularly among patients who were hospitalized for a respiratory cause or received ventilatory support. Trial registration ClinicalTrials.gov, NCT01915511. Registered 5 August 2013, https://clinicaltrials.gov/ct2/show/NCT01915511.

AB - Background: Hospitalizations are common among patients with idiopathic pulmonary fibrosis (IPF). We investigated the impact of hospitalizations on outcomes in patients with IPF. Methods: The IPF-PRO Registry is an observational US registry that enrolled patients with IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months. Associations between patient characteristics and hospitalization, and between hospitalization and mortality, were analyzed using Cox regression models. Results: A total of 1002 patients with IPF were enrolled into the IPF-PRO Registry. Over a median follow-up time of 23.7 months (maximum: 67.0 months), 568 patients (56.7%) had at least one hospitalization. Of these patients, 319 (56.2%) had at least one respiratory-related hospitalization and 120 (21.1%) had at least one hospitalization with ventilatory support. Younger age (HR 0.68 [95% CI 0.55, 0.84] per 5-year increase for patients < 62 years), lower BMI (0.96 [0.93, 0.98] per 1-point increase), lower FVC % predicted (0.90 [0.83, 0.97] per 10% increase), oxygen use at rest (2.85 [2.18, 3.72]) and history of pulmonary hypertension (2.02 [1.37, 2.96]) at enrollment were associated with an increased risk of respiratory-related hospitalization during follow-up. In a multivariable model, there was an eightfold increase in the risk of mortality during hospitalization or within 90 days of discharge compared with outside of this period. The risk of mortality associated with a respiratory hospitalization or a hospitalization with ventilatory support was even greater. Conclusions: Data from the IPF-PRO Registry demonstrate that hospitalizations are common among patients with IPF. The risk of mortality during hospitalization or within 90 days of discharge was high, particularly among patients who were hospitalized for a respiratory cause or received ventilatory support. Trial registration ClinicalTrials.gov, NCT01915511. Registered 5 August 2013, https://clinicaltrials.gov/ct2/show/NCT01915511.

KW - Interstitial lung disease

KW - Mechanical ventilation

KW - Mortality

KW - Pulmonary fibrosis

KW - Respiratory function tests

UR - http://www.scopus.com/inward/record.url?scp=85116509544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85116509544&partnerID=8YFLogxK

U2 - 10.1186/s12931-021-01851-4

DO - 10.1186/s12931-021-01851-4

M3 - Article

C2 - 34592998

SN - 1465-9921

VL - 22

JO - Respiratory research

JF - Respiratory research

IS - 1

M1 - 257

ER -

Hospitalizations in patients with idiopathic pulmonary fibrosis

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this